Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

被引：5

作者：

Juarez-Salcedo, Luis Miguel ^{[1
]}

Nimkar, Santosh ^{[2
]}

Corazon, Ana Maria ^{[3
]}

Dalia, Samir ^{[4
]}

机构：

[1] La Princesa Univ Hosp, Hematol Dept, Madrid 28006, Spain

[2] Kansas City Univ, Coll Osteopath Med, Kansas City, MO 64804 USA

[3] Primary Care Hlth Ctr, Madrid, Spain

[4] Mercy Clin Oncol & Hematol, Hematol Oncol Dept, Joplin, MI 73120 USA

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2024年 / 25卷 / 14期

关键词：

immunotherapy; antibody-drug conjugate; diffuse large-B-cell lymphoma; refractory/relapse; loncastuximab tesirine; ANTIBODY-DRUG CONJUGATE; SINGLE-ARM; OPEN-LABEL; MULTICENTER; TRANSPLANTATION; CHEMOTHERAPY;

D O I：

10.3390/ijms25147580

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Currently, a significant percentage of patients with DLBCL are refractory or relapse after a first line of immunochemotherapy. Second relapses after autologous stem cell transplantation or chimeric antigen receptor T-cell therapies present few treatment options and do not yield good results. New molecules have entered the immunotherapy arsenal. Loncastuximab tesirine comprises a humanized anti-CD19 monoclonal conjugated antibody, which consists of an anti-CD19 antibody and cytotoxic alkylating agent, SG3199. Several studies have proven its efficacy in the treatment of refractory cases of DLBCL with a good safety profile, with the main adverse effects being neutropenia, thrombopenia, and liver enzyme involvement. In this review, we explain the mechanism of action of this molecule, the clinical data that have led to its acceptance by the FDA, and the new therapeutic options that are proposed in association with this drug.

引用

页数：9

共 35 条

[1] Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma [J].

Ahmed, Nausheen ;

Hamadani, Mehdi .

EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) :1313-1320

[2] Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study [J].

Caimi, Paolo F. ;

Ai, Weiyun Z. ;

Alderuccio, Juan Pablo ;

Ardeshna, Kirit M. ;

Hamadani, Mehdi ;

Hess, Brian ;

Kahl, Brad S. ;

Radford, John ;

Solh, Melhem ;

Stathis, Anastasios ;

Zinzani, Pier Luigi ;

Wang, Ying ;

Qin, Yajuan ;

Wang, Luqiang ;

Xu, Zhiying Cindy ;

Stella, Carmelo Carlo- .

HAEMATOLOGICA, 2024, 109 (04) :1184-1193

[3] The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy [J].

Caimi, Paolo F. ;

Ardeshna, Kirit M. ;

Reid, Erin ;

Ai, Weiyun ;

Lunning, Matthew ;

Zain, Jasmine ;

Solh, Melhem ;

Kahl, Brad S. ;

Hamadani, Mehdi .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (05) :E335-E339

[4] Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial [J].

Caimi, Paolo F. ;

Ai, Weiyun ;

Alderuccio, Juan Pablo ;

Ardeshna, Kirit M. ;

Hamadani, Mehdi ;

Hess, Brian ;

Kahl, Brad S. ;

Radford, John ;

Solh, Melhem ;

Stathis, Anastasios ;

Zinzani, Pier Luigi ;

Havenith, Karin ;

Feingold, Jay ;

He, Shui ;

Qin, Yajuan ;

Ungar, David ;

Zhang, Xiaoyan ;

Carlo-Stella, Carmelo .

LANCET ONCOLOGY, 2021, 22 (06) :790-800

[5] The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma [J].

Calabretta, Eleonora ;

Hamadani, Mehdi ;

Zinzani, Pier Luigi ;

Caimi, Paolo ;

Carlo-Stella, Carmelo .

BLOOD, 2022, 140 (04) :303-308

[6]

Carlo-Stella C, 2023, Hematol Oncol, V41 Suppl 2, P850, DOI 10.1002/hon.3166_OT29

[7] Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [J].

Chapuy, Bjoern ;

Stewart, Chip ;

Dunford, Andrew J. ;

Kim, Jaegil ;

Kamburov, Atanas ;

Redd, Robert A. ;

Lawrence, Mike S. ;

Roemer, Margaretha G. M. ;

Li, Amy J. ;

Ziepert, Marita ;

Staiger, Annette M. ;

Wala, Jeremiah A. ;

Ducar, Matthew D. ;

Leshchiner, Ignaty ;

Rheinbay, Ester ;

Taylor-Weiner, Amaro ;

Coughlin, Caroline A. ;

Hess, Julian M. ;

Pedamallu, Chandra S. ;

Livitz, Dimitri ;

Rosebrock, Daniel ;

Rosenberg, Mara ;

Tracy, Adam A. ;

Horn, Heike ;

van Hummelen, Paul ;

Feldman, Andrew L. ;

Link, Brian K. ;

Novak, Anne J. ;

Cerhan, James R. ;

Habermann, Thomas M. ;

Siebert, Reiner ;

Rosenwald, Andreas ;

Thorner, Aaron R. ;

Meyerson, Matthew L. ;

Golub, Todd R. ;

Beroukhim, Rameen ;

Wulf, Gerald G. ;

Ott, German ;

Rodig, Scott J. ;

Monti, Stefano ;

Neuberg, Donna S. ;

Loeffler, Markus ;

Pfreundschuh, Michael ;

Truemper, Lorenz ;

Getz, Gad ;

Shipp, Margaret A. .

NATURE MEDICINE, 2018, 24 (05) :679-+

[8] Antibody-drug conjugates for cancer [J].

Chau, Cindy H. ;

Steeg, Patricia S. ;

Figg, William D. .

LANCET, 2019, 394 (10200) :793-804

[9] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].

Cheson, BD ;

Horning, SJ ;

Coiffier, B ;

Shipp, MA ;

Fisher, RI ;

Connors, JM ;

Lister, TA ;

Vose, J ;

Grillo-López, A ;

Hagenbeek, A ;

Cabanillas, F ;

Klippensten, D ;

Hiddemann, W ;

Castellino, R ;

Harris, NL ;

Armitage, JO ;

Carter, W ;

Hoppe, R ;

Canellos, GP .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253

[10] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

← 1 2 3 4 →